NURS 5334 Advanced Pharmacology Quiz 2 Test
Bank | UTA | Verified Questions and Answers |
100% Correct | A+ Graded (2026–2027)
1|Page
,NURS 5334 Advanced Pharmacology Quiz 2 Test Bank
2026/2027 Examination
Total Questions: 200
Instructions:
• Answer all questions.
• Select the single best answer.
• Each question has four answer choices: A, B, C, and D.
• Select only ONE answer for each question.
SECTION 1: Pharmacokinetics & Pharmacodynamics
Questions 1–40
Q1. A 68-year-old patient with Stage 3 chronic kidney disease is prescribed a medication that
undergoes extensive renal tubular secretion. Which pharmacokinetic parameter is most directly
affected by this patient's renal function, necessitating a dosage adjustment?
A. Bioavailability
B. Volume of distribution
C. Clearance
D. Protein binding
Correct Answer: C. Clearance
Rationale: Clearance is the volume of plasma from which a drug is completely removed per unit
time. Renal tubular secretion is a major mechanism of drug elimination, and impairment reduces
clearance, leading to drug accumulation. Bioavailability reflects absorption, volume of distribution
reflects tissue distribution, and protein binding affects the free fraction but not the rate of
elimination per se.
Q2. A patient is prescribed a drug that follows first-order elimination kinetics. The half-life of the
drug is 6 hours. Approximately how long will it take for the drug to reach steady-state plasma
concentration with a constant dosing regimen?
A. 6 hours
B. 12 hours
C. 24 hours
D. 48 hours
Correct Answer: C. 24 hours
Rationale: Steady state is achieved after approximately 4 to 5 half-lives. With a half-life of 6
hours, 4 half-lives equal 24 hours. At steady state, the rate of drug administration equals the rate of
elimination, and plasma concentration remains relatively constant.
2|Page
, Q3. A patient with severe hypoalbuminemia is prescribed phenytoin, a highly protein-bound
drug. The prescriber should anticipate which alteration in drug effect?
A. Decreased free drug concentration and reduced therapeutic effect
B. Increased free drug concentration and enhanced therapeutic effect with potential toxicity
C. No change in free drug concentration because total drug levels remain therapeutic
D. Increased protein binding to compensate for low albumin levels
Correct Answer: B. Increased free drug concentration and enhanced therapeutic effect with
potential toxicity
Rationale: Only the unbound (free) fraction of a drug is pharmacologically active. In
hypoalbuminemia, fewer binding sites are available, leading to a higher free fraction of phenytoin.
This can produce exaggerated therapeutic effects and toxicity even when total drug levels appear
within the normal range.
Q4. Which statement best describes the mechanism by which a noncompetitive antagonist
reduces the maximal efficacy of an agonist?
A. It binds to the same site as the agonist and prevents receptor activation
B. It binds to an allosteric site and irreversibly alters the receptor or a downstream component
C. It increases the agonist's affinity for the receptor
D. It competes with the agonist for plasma protein binding sites
Correct Answer: B. It binds to an allosteric site and irreversibly alters the receptor or a
downstream component
Rationale: Noncompetitive antagonists bind to sites distinct from the agonist binding site. They
either irreversibly modify the receptor or interfere with a downstream signaling component, thereby
reducing the maximal response that can be achieved regardless of agonist concentration.
Competitive antagonists shift the dose-response curve to the right but do not reduce maximal
efficacy.
Q5. A patient is prescribed two drugs. Drug X is a potent inducer of CYP3A4, and Drug Y is a
substrate of CYP3A4 with a narrow therapeutic index. Which clinical consequence should the
prescriber anticipate?
A. Increased plasma levels of Drug Y and risk of toxicity
B. Decreased plasma levels of Drug Y and risk of therapeutic failure
C. No significant interaction because Drug Y is a substrate, not an inhibitor
D. Increased renal excretion of Drug Y without hepatic involvement
Correct Answer: B. Decreased plasma levels of Drug Y and risk of therapeutic failure
Rationale: CYP3A4 inducers accelerate the metabolism of substrate drugs, reducing their plasma
concentrations. For a drug with a narrow therapeutic index, this can lead to subtherapeutic levels
3|Page
, and loss of efficacy. The prescriber may need to increase the dose of Drug Y or select an alternative
agent.
Q6. A weak base drug with a pKa of 8.4 is administered orally. In which environment will this
drug be predominantly non-ionized and therefore most readily absorbed by passive diffusion?
A. Stomach (pH 1.5)
B. Duodenum (pH 6.0)
C. Jejunum (pH 7.0)
D. Distal ileum (pH 8.0)
Correct Answer: D. Distal ileum (pH 8.0)
Rationale: Weak bases are predominantly non-ionized in alkaline environments. At a pH above
its pKa (8.4), the drug exists largely in its non-ionized, lipid-soluble form, which facilitates passive
diffusion across cell membranes. The distal ileum provides the most alkaline environment among the
choices.
Q7. A 72-year-old patient has decreased lean body mass and increased body fat percentage
compared with younger adults. How will this alteration affect the volume of distribution and half-life
of a highly lipid-soluble drug?
A. Decreased volume of distribution and decreased half-life
B. Decreased volume of distribution and increased half-life
C. Increased volume of distribution and prolonged half-life
D. Increased volume of distribution and shortened half-life
Correct Answer: C. Increased volume of distribution and prolonged half-life
Rationale: In older adults, increased body fat serves as a larger storage depot for lipid-soluble
drugs, expanding the volume of distribution. A larger volume of distribution means less drug remains
in plasma for elimination, prolonging the half-life and duration of action.
Q8. A patient is administered a drug that is a competitive antagonist at beta-adrenergic
receptors. If a high dose of a beta-agonist is subsequently administered, what effect will be
observed?
A. The antagonist will be displaced, and the agonist's maximal effect will be restored
B. The antagonist's effect will be potentiated
C. The agonist will produce an enhanced response beyond its normal maximum
D. The antagonist will irreversibly block the receptor
Correct Answer: A. The antagonist will be displaced, and the agonist's maximal effect will be
restored
Rationale: Competitive antagonists bind reversibly to the same receptor site as agonists.
Increasing the concentration of the agonist can outcompete the antagonist for binding, eventually
restoring the agonist's full maximal efficacy. This is a hallmark of competitive antagonism.
4|Page
Bank | UTA | Verified Questions and Answers |
100% Correct | A+ Graded (2026–2027)
1|Page
,NURS 5334 Advanced Pharmacology Quiz 2 Test Bank
2026/2027 Examination
Total Questions: 200
Instructions:
• Answer all questions.
• Select the single best answer.
• Each question has four answer choices: A, B, C, and D.
• Select only ONE answer for each question.
SECTION 1: Pharmacokinetics & Pharmacodynamics
Questions 1–40
Q1. A 68-year-old patient with Stage 3 chronic kidney disease is prescribed a medication that
undergoes extensive renal tubular secretion. Which pharmacokinetic parameter is most directly
affected by this patient's renal function, necessitating a dosage adjustment?
A. Bioavailability
B. Volume of distribution
C. Clearance
D. Protein binding
Correct Answer: C. Clearance
Rationale: Clearance is the volume of plasma from which a drug is completely removed per unit
time. Renal tubular secretion is a major mechanism of drug elimination, and impairment reduces
clearance, leading to drug accumulation. Bioavailability reflects absorption, volume of distribution
reflects tissue distribution, and protein binding affects the free fraction but not the rate of
elimination per se.
Q2. A patient is prescribed a drug that follows first-order elimination kinetics. The half-life of the
drug is 6 hours. Approximately how long will it take for the drug to reach steady-state plasma
concentration with a constant dosing regimen?
A. 6 hours
B. 12 hours
C. 24 hours
D. 48 hours
Correct Answer: C. 24 hours
Rationale: Steady state is achieved after approximately 4 to 5 half-lives. With a half-life of 6
hours, 4 half-lives equal 24 hours. At steady state, the rate of drug administration equals the rate of
elimination, and plasma concentration remains relatively constant.
2|Page
, Q3. A patient with severe hypoalbuminemia is prescribed phenytoin, a highly protein-bound
drug. The prescriber should anticipate which alteration in drug effect?
A. Decreased free drug concentration and reduced therapeutic effect
B. Increased free drug concentration and enhanced therapeutic effect with potential toxicity
C. No change in free drug concentration because total drug levels remain therapeutic
D. Increased protein binding to compensate for low albumin levels
Correct Answer: B. Increased free drug concentration and enhanced therapeutic effect with
potential toxicity
Rationale: Only the unbound (free) fraction of a drug is pharmacologically active. In
hypoalbuminemia, fewer binding sites are available, leading to a higher free fraction of phenytoin.
This can produce exaggerated therapeutic effects and toxicity even when total drug levels appear
within the normal range.
Q4. Which statement best describes the mechanism by which a noncompetitive antagonist
reduces the maximal efficacy of an agonist?
A. It binds to the same site as the agonist and prevents receptor activation
B. It binds to an allosteric site and irreversibly alters the receptor or a downstream component
C. It increases the agonist's affinity for the receptor
D. It competes with the agonist for plasma protein binding sites
Correct Answer: B. It binds to an allosteric site and irreversibly alters the receptor or a
downstream component
Rationale: Noncompetitive antagonists bind to sites distinct from the agonist binding site. They
either irreversibly modify the receptor or interfere with a downstream signaling component, thereby
reducing the maximal response that can be achieved regardless of agonist concentration.
Competitive antagonists shift the dose-response curve to the right but do not reduce maximal
efficacy.
Q5. A patient is prescribed two drugs. Drug X is a potent inducer of CYP3A4, and Drug Y is a
substrate of CYP3A4 with a narrow therapeutic index. Which clinical consequence should the
prescriber anticipate?
A. Increased plasma levels of Drug Y and risk of toxicity
B. Decreased plasma levels of Drug Y and risk of therapeutic failure
C. No significant interaction because Drug Y is a substrate, not an inhibitor
D. Increased renal excretion of Drug Y without hepatic involvement
Correct Answer: B. Decreased plasma levels of Drug Y and risk of therapeutic failure
Rationale: CYP3A4 inducers accelerate the metabolism of substrate drugs, reducing their plasma
concentrations. For a drug with a narrow therapeutic index, this can lead to subtherapeutic levels
3|Page
, and loss of efficacy. The prescriber may need to increase the dose of Drug Y or select an alternative
agent.
Q6. A weak base drug with a pKa of 8.4 is administered orally. In which environment will this
drug be predominantly non-ionized and therefore most readily absorbed by passive diffusion?
A. Stomach (pH 1.5)
B. Duodenum (pH 6.0)
C. Jejunum (pH 7.0)
D. Distal ileum (pH 8.0)
Correct Answer: D. Distal ileum (pH 8.0)
Rationale: Weak bases are predominantly non-ionized in alkaline environments. At a pH above
its pKa (8.4), the drug exists largely in its non-ionized, lipid-soluble form, which facilitates passive
diffusion across cell membranes. The distal ileum provides the most alkaline environment among the
choices.
Q7. A 72-year-old patient has decreased lean body mass and increased body fat percentage
compared with younger adults. How will this alteration affect the volume of distribution and half-life
of a highly lipid-soluble drug?
A. Decreased volume of distribution and decreased half-life
B. Decreased volume of distribution and increased half-life
C. Increased volume of distribution and prolonged half-life
D. Increased volume of distribution and shortened half-life
Correct Answer: C. Increased volume of distribution and prolonged half-life
Rationale: In older adults, increased body fat serves as a larger storage depot for lipid-soluble
drugs, expanding the volume of distribution. A larger volume of distribution means less drug remains
in plasma for elimination, prolonging the half-life and duration of action.
Q8. A patient is administered a drug that is a competitive antagonist at beta-adrenergic
receptors. If a high dose of a beta-agonist is subsequently administered, what effect will be
observed?
A. The antagonist will be displaced, and the agonist's maximal effect will be restored
B. The antagonist's effect will be potentiated
C. The agonist will produce an enhanced response beyond its normal maximum
D. The antagonist will irreversibly block the receptor
Correct Answer: A. The antagonist will be displaced, and the agonist's maximal effect will be
restored
Rationale: Competitive antagonists bind reversibly to the same receptor site as agonists.
Increasing the concentration of the agonist can outcompete the antagonist for binding, eventually
restoring the agonist's full maximal efficacy. This is a hallmark of competitive antagonism.
4|Page
